Please assess the completion status of the following clinical trial:

Trial Title: Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult, ≥18 years of age at the time of informed consent~* A new, valid prescription for XERMELO~* Initiating XERMELO for the treatment of carcinoid syndrome~* Able and willing to provide informed consent prior to participation in the study~Exclusion Criteria:~* Unable to understand and read English~* Unable to access the internet~* Prior exposure to XERMELO

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Carcinoid Syndrome patients initiating Xermelo (Type: None): Patients with Carcinoid Syndrome who are initiating treatment with XERMELO.

Based on this trial design, predict the completion outcome and termination type (if applicable).